
|Videos|December 20, 2016
Dr. Fedyanin on Future Treatment Landscape of CRC
Author(s)Mikhail Fedyanin, MD, PhD
Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses future approaches for the treatment of patients with colorectal cancer (CRC).
Advertisement
Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses future approaches for the treatment of patients with colorectal cancer (CRC).
There will hopefully be more novel agents approved in the CRC space, Fedyanin explains, such as combination regimens of MEK inhibitors and PD-1 inhibitors. Additionally, he predicts and anticipates more research dedicated to treatments for patients with CRC who harbor KRAS mutations. Currently, there are a lack of effective agents able to target this patient population.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5



































